Bioreactor and Thiel Cadaver-based Feasibility Evaluations of a Novel Magnesium Wireform Bioresorbable Vascular Scaffold

基于生物反应器和泰尔尸体的新型镁线状生物可吸收血管支架的可行性评估

• 批准号: 133772
• 金额: $ 17.58万
• 依托单位: MEDALLIANCE LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133772
• 关键词: Bioreactor; Thiel; Cadaver; based; Feasibility

"S-Bahn Medical is a medical device company based in Glasgow, Scotland who are developing a Bioresorbable Vascular Scaffold (BVS) or resorbable stent for the treatment of atherosclerosis. Atherosclerosis occurs due to the accumulation of plaque in an artery causing it to narrow and reduce blood flow to and from the heart. This condition is commonly referred to as Cardiovascular Disease (CVD). Since the 1980's such narrowing of vessel lumen has been treatable by minimally invasive, catheter based medical device technologies that expand the narrowed vessel lumen to its native diameter. Over time these methods have developed significantly in their effectiveness to treat arteriosclerosis through new stent developments. S-Bahn Medical's current BVS is the next step in improving these treatments. Unlike conventional stents, bioresorbable vascular scaffolds (BVS) will dissolve in the body after initially providing the needed mechanical support to the expanded vessel. Conventional stents cannot resorb, and over time can become detrimental to patient health. In recent years there has been some success and development in this emerging technology. However, some key issues in these BVS designs have limited their effectiveness to treat patients compared to conventional non-resorbable stents. S-Bahn Medical's concept BVS, address these design limitations to improve overall treatment of Cardiovascular Disease in the UK and across the world.With the Innovate UK funding, S-Bahn Medical will carry out their first in vitro and cadaver studies of their device in collaboration with the Golden Jubilee National Hospital."

S-巴恩医疗公司是一家总部位于苏格兰格拉斯哥的医疗器械公司，他们正在开发一种用于治疗动脉粥样硬化的生物可吸收血管支架(BVS)或可再吸收支架。动脉粥样硬化是由于动脉中的斑块积聚，导致动脉变窄，减少进出心脏的血流量而导致的。这种情况通常被称为心血管疾病(CVD)。自20世纪80年代S以来，这种管腔狭窄已经可以通过微创、基于导管的医疗设备技术来治疗，这种技术可以将狭窄的血管管腔扩大到其自然直径。随着时间的推移，这些方法在通过新的支架开发来治疗动脉硬化方面的有效性已经有了显着的发展。S-巴恩医疗公司目前的BVS是改进这些治疗方法的下一步。与传统支架不同，生物可吸收血管支架(BVS)在最初为扩张的血管提供所需的机械支持后，会在体内溶解。传统的支架不能再吸收，随着时间的推移，可能会损害患者的健康。近年来，这项新兴技术取得了一些成功和发展。然而，与传统的非可吸收支架相比，这些BVS设计中的一些关键问题限制了它们对患者的治疗效果。S-巴恩医疗公司的概念BVS解决了这些设计限制，以改善英国和世界各地心血管疾病的整体治疗。在Innovate UK的资助下，S-巴恩医疗公司将与金禧国家医院合作，对他们的设备进行第一次体外和身体研究。